Sso7d Glycan-Binding Protein Scaffolds for Monosaccharide Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing carbohydrate-binding proteins are typically large and unable to specifically recognize or bind to single monosaccharide or disaccharide determinants, limiting their applications in immunological, therapeutic, and diagnostic roles.
Innovation Solution
Utilizing a small DNA-binding protein scaffold, such as Sso7d, which is mutated and evolved to create glycan-binding proteins with specific binding sites for monosaccharides or disaccharides, allowing for high affinity and selectivity through directed evolution techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing carbohydrate-binding proteins are used, then binding function is provided, but the proteins are large and unable to specifically recognize or bind to single monosaccharide or disaccharide determinants
Solution Approach 1:
The patent segments the binding function from the overall protein structure by using only small peptide fragments (6-20 amino acids) that contain the specific glycan-binding determinants. These minimal binding units can specifically recognize monosaccharides or disaccharides without requiring the full-size protein structure, thereby achieving high binding specificity with reduced complexity.
Solution Approach 2:
The invention extracts the essential binding determinant sequences from larger carbohydrate-binding proteins. By identifying and isolating the specific amino acid sequences (such as those containing R-X5-R-X5-R motifs) that are responsible for glycan binding, the patent creates minimal functional units that retain binding specificity while eliminating unnecessary protein mass and structural complexity.
2Adaptability or versatility
If existing carbohydrate-binding proteins are used, then binding function is provided, but they limit applications in immunological, therapeutic, and diagnostic roles
Solution Approach 1:
The patent creates universal glycan-binding peptide fragments that can be applied across multiple fields including immunological assays, therapeutic conjugates, and diagnostic tools. These minimal binding units serve as versatile building blocks that can be integrated into various platforms (ELISAs, flow cytometry, imaging agents) without requiring field-specific protein engineering, thereby expanding application range while maintaining simplicity.
Data Source
AI summary
Glycan-binding proteins, and compositions thereof, are generally described, including methods of making and using such proteins. The proteins may include scaffolds based on easily evolvable DNA-binding proteins, with binding sites able to specifically bind to mono- or disaccharides, such as monosaccharide-binding determinants, disaccharide-binding determinants, more complex carbohydrates, etc. In certain aspects, a protein may be generated starting from a small DNA-binding protein, such as Sso7d. Such glycan-binding proteins may have numerous applications, including in enzyme-linked immunosorbent assays (ELISAs), glycan characterization, cell selection, flow cytometry, histology, imaging, arrays, affinity purification, enzyme-linked visualization, binding to a target for pharmaceutical purposes, etc.